Genetic Testing for Neurological Disorders Market - Strategic Insights and Forecasts (2026-2035)

Description

The Global Genetic Testing for Neurological Disorders Market is forecast to grow at a CAGR of 8.9%, reaching USD 1,872.94 million in 2035 from USD 797.54 million in 2026.

The global genetic testing for neurological disorders market is experiencing robust growth as advances in genomic medicine, sequencing technologies, and precision healthcare transform the diagnosis and management of neurological diseases. Genetic testing has become an increasingly important tool for identifying inherited neurological disorders, understanding disease susceptibility, supporting personalized treatment strategies, and improving clinical decision-making. The growing recognition of genetic factors underlying conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, autism spectrum disorders, muscular dystrophies, hereditary neuropathies, and rare neurogenetic syndromes is driving widespread adoption of genetic testing solutions.

The market is benefiting from significant advances in next-generation sequencing (NGS), whole-exome sequencing, whole-genome sequencing, and molecular diagnostic technologies. These innovations have improved testing accuracy, reduced turnaround times, and lowered sequencing costs, making genetic testing more accessible to healthcare providers and patients. As neurological diseases continue to represent a major global healthcare burden, clinicians increasingly rely on genetic insights to support early diagnosis, risk assessment, disease classification, and treatment selection.

Growing awareness of personalized medicine is further accelerating market expansion. Healthcare systems are increasingly emphasizing individualized treatment approaches that leverage genetic information to optimize therapeutic outcomes. In neurological disorders, genetic testing can help identify disease-causing mutations, predict disease progression, support family planning decisions, and enable participation in targeted clinical trials. These capabilities are expanding the role of genetic testing throughout the neurological care continuum.

The market is also supported by increasing investments in neuroscience research, expanding genomic databases, government initiatives promoting rare disease diagnosis, and growing collaboration between diagnostic companies, healthcare providers, and research institutions. As precision neurology continues to evolve, genetic testing is expected to become an increasingly essential component of neurological disease management worldwide.

Market Drivers

Increasing Prevalence of Neurological Disorders

The growing incidence of neurological disorders is a major factor driving market growth. Neurodegenerative diseases, inherited neurological conditions, developmental disorders, and epilepsy continue to affect millions of individuals globally.

Genetic testing enables earlier and more accurate diagnosis, particularly for conditions with complex clinical presentations or overlapping symptoms. Improved diagnostic capabilities are supporting greater utilization across neurological care settings.

Advancements in Sequencing Technologies

Technological innovation has significantly improved the performance and affordability of genetic testing. Next-generation sequencing platforms can analyze multiple genes simultaneously while providing comprehensive genomic insights.

The ability to identify rare mutations, repeat expansions, and complex genetic variants is enhancing diagnostic accuracy and expanding clinical applications in neurology.

Growing Adoption of Precision Medicine

Healthcare providers increasingly recognize the value of personalized medicine in managing neurological disorders. Genetic testing supports individualized treatment strategies by identifying disease mechanisms and predicting therapeutic responses.

This shift toward precision healthcare is creating substantial demand for genomic testing services and specialized neurological diagnostic solutions.

Rising Demand for Early Diagnosis

Early diagnosis is becoming increasingly important for neurological disorders, particularly as disease-modifying therapies and targeted treatments emerge.

Genetic testing can identify at-risk individuals before symptom onset, enabling earlier intervention, improved disease monitoring, and more effective clinical management.

Expansion of Rare Disease Testing Programs

Rare neurological disorders often present significant diagnostic challenges due to their genetic complexity and low prevalence. Genetic testing is becoming a critical tool for identifying rare disease-causing mutations and reducing diagnostic delays.

Government initiatives, patient advocacy efforts, and increased awareness of rare diseases are contributing to broader adoption of genetic testing services.

Market Restraints

High Testing Costs

Although sequencing costs have declined substantially, comprehensive genetic testing can still be expensive, particularly in regions with limited reimbursement support.

Cost-related barriers may restrict patient access and slow adoption in certain healthcare systems.

Ethical and Privacy Concerns

Genetic testing generates highly sensitive personal information, raising concerns related to privacy, data security, informed consent, and potential discrimination.

Healthcare providers and diagnostic organizations must address these concerns through robust regulatory compliance and patient education programs.

Limited Access in Developing Regions

Access to advanced genetic testing infrastructure remains limited in many emerging economies. Shortages of specialized laboratories, trained genetic counselors, and reimbursement mechanisms may constrain market growth in certain regions.

Continued investments in healthcare infrastructure will be necessary to improve accessibility.

Technology and Segment Insights

By Test Type

Next-generation sequencing represents the largest and fastest-growing technology segment due to its ability to analyze multiple genes efficiently and accurately. NGS-based panels are increasingly used for diagnosing epilepsy, neurodevelopmental disorders, hereditary neuropathies, and neurodegenerative diseases.

Whole-exome sequencing is widely utilized for identifying disease-causing variants within protein-coding regions, particularly in rare and undiagnosed neurological disorders. Whole-genome sequencing is gaining adoption as sequencing costs decline and analytical capabilities improve.

By Disorder Type

Neurodegenerative diseases represent a significant market segment, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

Epilepsy and seizure disorders constitute another major application area due to the strong genetic contribution associated with many epilepsy syndromes. Autism spectrum disorders, intellectual disabilities, hereditary neuropathies, and neuromuscular disorders also contribute substantially to market demand.

By End User

Diagnostic laboratories account for a major share of the market due to their specialized testing capabilities and expanding partnerships with healthcare providers. Advanced laboratory infrastructure supports comprehensive genomic analysis and interpretation services.

Hospitals and specialty neurology clinics increasingly integrate genetic testing into routine clinical practice for diagnosis, treatment planning, and patient management. Research institutions also represent an important segment due to extensive neurological genetics research activities.

By Application

Diagnostic testing remains the largest application segment, driven by demand for accurate disease identification and classification.

Predictive testing is gaining traction as healthcare providers seek to identify individuals at elevated genetic risk for neurological disorders. Carrier testing, prenatal testing, and pharmacogenomic testing are also expanding as genomic medicine becomes more integrated into neurological care pathways.

Regional Insights

North America dominates the global genetic testing for neurological disorders market due to advanced genomic research infrastructure, strong healthcare spending, widespread adoption of precision medicine, and the presence of leading diagnostic companies. The region benefits from substantial investments in neuroscience research and personalized healthcare initiatives.

Europe represents a significant market supported by expanding genomic medicine programs, strong regulatory frameworks, and increasing utilization of genetic diagnostics within neurological care. Government-supported healthcare systems continue to facilitate patient access to advanced testing services.

Asia Pacific is expected to experience the fastest growth during the forecast period. Rising healthcare expenditures, increasing awareness of genetic disorders, expanding sequencing capabilities, and growing investments in precision medicine are driving adoption across China, Japan, India, South Korea, and Southeast Asia. India is expected to demonstrate particularly strong growth due to increasing diagnostic demand and expanding genomic healthcare initiatives.

Latin America and the Middle East & Africa are gradually improving access to genetic testing through healthcare modernization efforts and expanding diagnostic infrastructure.

Competitive and Strategic Outlook

The genetic testing for neurological disorders market is characterized by continuous technological innovation, strategic partnerships, and increasing investments in genomic medicine. Diagnostic companies are focusing on expanding test menus, improving analytical capabilities, and developing specialized neurological testing panels.

Competition is centered on testing accuracy, turnaround time, data interpretation capabilities, and clinical utility. Companies are increasingly integrating artificial intelligence, bioinformatics platforms, and advanced genomic analytics to improve diagnostic performance and support clinical decision-making.

Strategic collaborations among diagnostic laboratories, biotechnology companies, academic institutions, and healthcare providers are accelerating research and expanding clinical adoption. As targeted therapies and precision neurology continue to advance, demand for comprehensive genetic testing solutions is expected to strengthen significantly.

Conclusion

The global genetic testing for neurological disorders market is poised for sustained growth as advances in genomics, sequencing technologies, and precision medicine continue to transform neurological healthcare. Rising prevalence of neurological diseases, increasing demand for early diagnosis, growing adoption of personalized medicine, and expanding rare disease testing programs are expected to drive market expansion. While challenges related to cost, access, and ethical considerations remain, genetic testing is becoming an indispensable tool for diagnosing, managing, and understanding neurological disorders, supporting improved patient outcomes and the future evolution of precision neurology.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

Product Code: KSI-008772

1. Executive Summary

1.1 Market Overview
1.2 Scope of the Report
1.3 Definition of Genetic Testing for Neurological Disorders
1.4 Key Market Insights
1.5 Market Snapshot by Testing Technology
1.6 Market Snapshot by Disorder Type
1.7 Market Snapshot by End User
1.8 Key Trends and Strategic Insights
1.9 Analyst Recommendations
1.10 Future Growth Outlook

2. Disease & Epidemiology Analysis

2.1 Introduction to Neurological Disorders with Genetic Basis
2.2 Genetic Architecture of Neurological Disorders
- 2.2.1 Monogenic Neurological Disorders
- 2.2.2 Polygenic Neurological Disorders
- 2.2.3 Mitochondrial Genetic Disorders
- 2.2.4 Chromosomal Abnormalities and Repeat Expansion Disorders
2.3 Epidemiology Overview
- 2.3.1 Global Disease Burden
- 2.3.2 Diagnosed Patient Population
- 2.3.3 Genetically Eligible Patient Population
- 2.3.4 Hereditary Risk Distribution
2.4 Epidemiology by Disorder Type
- 2.4.1 Alzheimer's Disease
- 2.4.2 Parkinson's Disease
- 2.4.3 Huntington's Disease
- 2.4.4 Amyotrophic Lateral Sclerosis (ALS)
- 2.4.5 Spinal Muscular Atrophy (SMA)
- 2.4.6 Duchenne Muscular Dystrophy (DMD)
- 2.4.7 Charcot-Marie-Tooth Disease
- 2.4.8 Epilepsy Syndromes
- 2.4.9 Ataxias
- 2.4.10 Fragile X Syndrome
- 2.4.11 Rett Syndrome
- 2.4.12 Neurometabolic Disorders
2.5 Biomarker and Mutation Landscape
- 2.5.1 SNVs and CNVs
- 2.5.2 Repeat Expansion Mutations
- 2.5.3 Mitochondrial DNA Mutations
- 2.5.4 APOE Genotyping
- 2.5.5 SMN1 and SMN2 Mutations
- 2.5.6 HTT Gene Expansions
- 2.5.7 LRRK2 and GBA Mutations
2.6 Genetic Counseling and Testing Eligibility
2.7 Diagnostic Pathway and Patient Journey
2.8 Unmet Needs in Early Diagnosis

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Rising Prevalence of Neurogenetic Disorders
- 3.2.2 Expansion of Precision Medicine
- 3.2.3 Increasing Adoption of Next-Generation Sequencing (NGS)
- 3.2.4 Growing Availability of Companion Diagnostics
- 3.2.5 Increasing Awareness of Hereditary Neurological Conditions
- 3.2.6 Expansion of Newborn Screening Programs
- 3.2.7 Advancements in Bioinformatics and AI-Based Genomic Interpretation
3.3 Market Restraints
- 3.3.1 High Cost of Comprehensive Genetic Testing
- 3.3.2 Limited Reimbursement Coverage
- 3.3.3 Ethical and Privacy Concerns
- 3.3.4 Variability in Regulatory Standards
- 3.3.5 Limited Access to Genetic Counseling
3.4 Market Opportunities
- 3.4.1 Expansion of Liquid Biopsy and Non-Invasive Genomics
- 3.4.2 Integration of Multi-Omics Approaches
- 3.4.3 Growth in Direct-to-Consumer Genetic Services
- 3.4.4 Emerging Markets Penetration
- 3.4.5 Expansion of Rare Disease Screening Initiatives
3.5 Market Challenges
- 3.5.1 Interpretation of Variants of Uncertain Significance (VUS)
- 3.5.2 Data Storage and Genomic Infrastructure Requirements
- 3.5.3 Standardization Challenges Across Laboratories
- 3.5.4 Regulatory Complexity in Cross-Border Testing
3.6 Porter's Five Forces Analysis
3.7 PESTLE Analysis
3.8 Value Chain Analysis
3.9 Pricing Analysis
3.10 Technology Adoption Trends
3.11 Investment and Funding Landscape

4. Commercial & Market Access

4.1 Reimbursement Landscape
- 4.1.1 Public Reimbursement Models
- 4.1.2 Private Insurance Coverage
- 4.1.3 Coding and Billing Frameworks
4.2 Health Technology Assessment (HTA) Trends
4.3 Market Access Challenges
4.4 Commercialization Strategies
4.5 Role of Reference Laboratories
4.6 Direct-to-Consumer vs Physician-Ordered Testing
4.7 Partnerships Between Diagnostic Firms and Pharmaceutical Companies
4.8 Patient Advocacy and Awareness Programs
4.9 Distribution and Commercial Networks
4.10 Pricing and Cost-Effectiveness Analysis

5. Innovation & Pipeline Landscape

5.1 Introduction to Emerging Genetic Testing Technologies
5.2 Pipeline Landscape Overview
5.3 Pipeline by Development Stage
- 5.3.1 Research Use Only (RUO) Assays
- 5.3.2 Clinical Validation Stage
- 5.3.3 Commercial Launch Stage
5.4 Pipeline by Testing Modality
- 5.4.1 Whole Genome Sequencing (WGS)
- 5.4.2 Whole Exome Sequencing (WES)
- 5.4.3 Targeted Gene Panels
- 5.4.4 PCR-Based Assays
- 5.4.5 Long-Read Sequencing
- 5.4.6 RNA Sequencing
- 5.4.7 Methylation Profiling
5.5 Innovation in Neurological Biomarker Discovery
5.6 AI and Machine Learning in Genetic Interpretation
5.7 Companion Diagnostic Development Trends
5.8 Liquid Biopsy and Cell-Free DNA Applications
5.9 Emerging CRISPR-Based Diagnostic Technologies
5.10 Strategic Collaborations and Licensing Agreements
5.11 Patent Landscape Analysis
5.12 Clinical Trial Landscape for Neurogenetic Diagnostics

6. Treatment Landscape

6.1 Current Treatment Paradigm for Neurological Disorders
6.2 Role of Genetic Testing in Treatment Selection
6.3 Precision Medicine and Targeted Therapy Integration
6.4 Approved Gene and Molecular Therapies Linked to Genetic Testing
- 6.4.1 Spinraza for SMA
- 6.4.2 Zolgensma for SMA
- 6.4.3 Evrysdi for SMA
- 6.4.4 Exondys 51 for DMD
- 6.4.5 Vyondys 53 for DMD
- 6.4.6 Skyclarys for Friedreich's Ataxia
6.5 Role of Pharmacogenomics in Neurology
6.6 Genetic Counseling and Clinical Decision Support
6.7 Emerging Personalized Therapeutic Approaches

7. Market Size & Forecast

7.1 Global Market Overview
7.2 Market Size Analysis (Historical: 2021-2024)
7.3 Market Forecast Analysis (2025-2032)
7.4 Market Growth Rate Analysis
7.5 Revenue Forecast by Testing Technology
7.6 Revenue Forecast by Disorder Type
7.7 Revenue Forecast by End User
7.8 Revenue Forecast by Region
7.9 Forecast Assumptions and Methodology

8. Market Segmentation

8.1 By Testing Technology
- 8.1.1 Next-Generation Sequencing (NGS)
- 8.1.2 Polymerase Chain Reaction (PCR)
- 8.1.3 Microarray Testing
- 8.1.4 Sanger Sequencing
- 8.1.5 Fluorescence In Situ Hybridization (FISH)
- 8.1.6 Multiplex Ligation-Dependent Probe Amplification (MLPA)
- 8.1.7 Whole Genome Sequencing
- 8.1.8 Whole Exome Sequencing
8.2 By Disorder Type
- 8.2.1 Neurodegenerative Disorders
- 8.2.2 Neuromuscular Disorders
- 8.2.3 Neurodevelopmental Disorders
- 8.2.4 Epileptic Disorders
- 8.2.5 Movement Disorders
- 8.2.6 Rare Genetic Neurological Disorders
8.3 By Sample Type
- 8.3.1 Blood Samples
- 8.3.2 Saliva Samples
- 8.3.3 Buccal Swab Samples
- 8.3.4 Tissue Samples
- 8.3.5 Cerebrospinal Fluid Samples
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Specialty Neurology Clinics
- 8.4.3 Diagnostic Laboratories
- 8.4.4 Academic and Research Institutes
- 8.4.5 Genetic Counseling Centers
8.5 By Distribution Channel
- 8.5.1 Direct Sales
- 8.5.2 Third-Party Distributors
- 8.5.3 Online Genetic Testing Platforms

9. Geographical Analysis

9.1 North America
- 9.1.1 Market Size and Forecast
- 9.1.2 Epidemiology and Demand Trends
- 9.1.3 Regional Regulatory Overview
- 9.1.4 Reimbursement Environment
- 9.1.5 Competitive Landscape
- 9.1.6 Technology Adoption Trends
9.2 Europe
- 9.2.1 Market Size and Forecast
- 9.2.2 Epidemiology and Demand Trends
- 9.2.3 Regional Regulatory Overview
- 9.2.4 Reimbursement Environment
- 9.2.5 Competitive Landscape
- 9.2.6 Technology Adoption Trends
9.3 Asia-Pacific
- 9.3.1 Market Size and Forecast
- 9.3.2 Epidemiology and Demand Trends
- 9.3.3 Regional Regulatory Overview
- 9.3.4 Reimbursement Environment
- 9.3.5 Competitive Landscape
- 9.3.6 Technology Adoption Trends
9.4 Latin America
- 9.4.1 Market Size and Forecast
- 9.4.2 Epidemiology and Demand Trends
- 9.4.3 Regional Regulatory Overview
- 9.4.4 Reimbursement Environment
- 9.4.5 Competitive Landscape
- 9.4.6 Technology Adoption Trends
9.5 Middle East & Africa
- 9.5.1 Market Size and Forecast
- 9.5.2 Epidemiology and Demand Trends
- 9.5.3 Regional Regulatory Overview
- 9.5.4 Reimbursement Environment
- 9.5.5 Competitive Landscape
- 9.5.6 Technology Adoption Trends

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size and Forecast
- 10.1.2 Epidemiology Overview
- 10.1.3 FDA Regulatory Framework
- 10.1.4 Reimbursement Scenario
- 10.1.5 Key Companies and Product Presence
10.2 Canada
- 10.2.1 Market Size and Forecast
- 10.2.2 Epidemiology Overview
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Scenario
- 10.2.5 Key Companies and Product Presence
10.3 Germany
- 10.3.1 Market Size and Forecast
- 10.3.2 Epidemiology Overview
- 10.3.3 Regulatory Framework
- 10.3.4 Reimbursement Scenario
- 10.3.5 Key Companies and Product Presence
10.4 United Kingdom
- 10.4.1 Market Size and Forecast
- 10.4.2 Epidemiology Overview
- 10.4.3 Regulatory Framework
- 10.4.4 Reimbursement Scenario
- 10.4.5 Key Companies and Product Presence
10.5 France
- 10.5.1 Market Size and Forecast
- 10.5.2 Epidemiology Overview
- 10.5.3 Regulatory Framework
- 10.5.4 Reimbursement Scenario
- 10.5.5 Key Companies and Product Presence
10.6 Italy
- 10.6.1 Market Size and Forecast
- 10.6.2 Epidemiology Overview
- 10.6.3 Regulatory Framework
- 10.6.4 Reimbursement Scenario
- 10.6.5 Key Companies and Product Presence
10.7 Spain
- 10.7.1 Market Size and Forecast
- 10.7.2 Epidemiology Overview
- 10.7.3 Regulatory Framework
- 10.7.4 Reimbursement Scenario
- 10.7.5 Key Companies and Product Presence
10.8 China
- 10.8.1 Market Size and Forecast
- 10.8.2 Epidemiology Overview
- 10.8.3 NMPA Regulatory Framework
- 10.8.4 Reimbursement Scenario
- 10.8.5 Key Companies and Product Presence
10.9 Japan
- 10.9.1 Market Size and Forecast
- 10.9.2 Epidemiology Overview
- 10.9.3 PMDA Regulatory Framework
- 10.9.4 Reimbursement Scenario
- 10.9.5 Key Companies and Product Presence
10.10 India
- 10.10.1 Market Size and Forecast
- 10.10.2 Epidemiology Overview
- 10.10.3 CDSCO Regulatory Framework
- 10.10.4 Reimbursement Scenario
- 10.10.5 Key Companies and Product Presence
10.11 South Korea
- 10.11.1 Market Size and Forecast
- 10.11.2 Epidemiology Overview
- 10.11.3 Regulatory Framework
- 10.11.4 Reimbursement Scenario
- 10.11.5 Key Companies and Product Presence
10.12 Australia
- 10.12.1 Market Size and Forecast
- 10.12.2 Epidemiology Overview
- 10.12.3 Regulatory Framework
- 10.12.4 Reimbursement Scenario
- 10.12.5 Key Companies and Product Presence
10.13 Brazil
- 10.13.1 Market Size and Forecast
- 10.13.2 Epidemiology Overview
- 10.13.3 Regulatory Framework
- 10.13.4 Reimbursement Scenario
- 10.13.5 Key Companies and Product Presence
10.14 Mexico
- 10.14.1 Market Size and Forecast
- 10.14.2 Epidemiology Overview
- 10.14.3 Regulatory Framework
- 10.14.4 Reimbursement Scenario
- 10.14.5 Key Companies and Product Presence
10.15 Saudi Arabia
- 10.15.1 Market Size and Forecast
- 10.15.2 Epidemiology Overview
- 10.15.3 Regulatory Framework
- 10.15.4 Reimbursement Scenario
- 10.15.5 Key Companies and Product Presence
10.16 South Africa
- 10.16.1 Market Size and Forecast
- 10.16.2 Epidemiology Overview
- 10.16.3 Regulatory Framework
- 10.16.4 Reimbursement Scenario
- 10.16.5 Key Companies and Product Presence

11. Regulatory & Policy Landscape

11.1 Overview of Global Regulatory Environment
11.2 United States Regulatory Framework
- 11.2.1 FDA Oversight of Genetic Tests
- 11.2.2 CLIA Certification Requirements
- 11.2.3 Laboratory Developed Tests (LDTs)
11.3 Europe Regulatory Framework
- 11.3.1 In Vitro Diagnostic Regulation (IVDR)
- 11.3.2 CE-IVD Requirements
11.4 Japan Regulatory Framework
- 11.4.1 PMDA Approval Pathways
- 11.4.2 Reimbursement and Pricing Regulations
11.5 India Regulatory Framework
- 11.5.1 CDSCO Medical Device and Diagnostic Regulations
- 11.5.2 National Rare Disease Policy Impact
11.6 China Regulatory Framework
- 11.6.1 NMPA Approval Process
- 11.6.2 Genomic Data Governance Policies
11.7 Data Privacy and Ethical Frameworks
11.8 Genetic Counseling and Informed Consent Regulations
11.9 International Guidelines and Standards
11.10 Regulatory Challenges and Future Reforms

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Strategic Positioning of Key Players
12.4 Product Portfolio Analysis
12.5 Technology Competitiveness Analysis
12.6 Mergers and Acquisitions
12.7 Strategic Collaborations and Partnerships
12.8 Investment and Funding Activities
12.9 New Product Launches
12.10 SWOT Analysis
12.11 Competitive Dashboard

13. Company Profiles

13.1 Illumina, Inc.
- 13.1.1 Company Overview
- 13.1.2 Neurological Genetic Testing Portfolio
  - 13.1.2.1 TruSight Neurodegeneration Kit
  - 13.1.2.2 NovaSeq Sequencing Systems
- 13.1.3 Key Neurological Applications
- 13.1.4 Strategic Collaborations
- 13.1.5 Financial Overview
13.2 Thermo Fisher Scientific Inc.
- 13.2.1 Company Overview
- 13.2.2 Genetic Testing Platforms
  - 13.2.2.1 Ion Torrent Genexus System
  - 13.2.2.2 Applied Biosystems Genetic Analysis Solutions
- 13.2.3 Neurology-Focused Applications
- 13.2.4 Strategic Developments
- 13.2.5 Financial Overview
13.3 F. Hoffmann-La Roche Ltd
- 13.3.1 Company Overview
- 13.3.2 Molecular Diagnostics Portfolio
  - 13.3.2.1 AVENIO Edge System
  - 13.3.2.2 Cobas Genetic Testing Solutions
- 13.3.3 Neurological Testing Applications
- 13.3.4 Strategic Initiatives
- 13.3.5 Financial Overview
13.4 QIAGEN N.V.
- 13.4.1 Company Overview
- 13.4.2 Neurological Genetic Testing Portfolio
  - 13.4.2.1 QIAseq Targeted DNA Panels
  - 13.4.2.2 Neurological Disorder Research Panels
- 13.4.3 Key Applications
- 13.4.4 Strategic Developments
- 13.4.5 Financial Overview
13.5 Bio-Rad Laboratories, Inc.
- 13.5.1 Company Overview
- 13.5.2 Digital PCR and Genetic Testing Portfolio
  - 13.5.2.1 Droplet Digital PCR Systems
  - 13.5.2.2 Genetic Analysis Assays
- 13.5.3 Neurology Applications
- 13.5.4 Strategic Developments
- 13.5.5 Financial Overview
13.6 Invitae Corporation
- 13.6.1 Company Overview
- 13.6.2 Neurological Genetic Testing Panels
  - 13.6.2.1 Comprehensive Neurological Disorders Panel
  - 13.6.2.2 Hereditary Parkinson Disease Panel
- 13.6.3 Key Indications
- 13.6.4 Strategic Collaborations
- 13.6.5 Financial Overview
13.7 GeneDx Holdings Corp.
- 13.7.1 Company Overview
- 13.7.2 Neurological Genetic Testing Services
  - 13.7.2.1 Whole Exome Sequencing Services
  - 13.7.2.2 Pediatric Neurology Testing Portfolio
- 13.7.3 Key Applications
- 13.7.4 Strategic Initiatives
- 13.7.5 Financial Overview
13.8 Centogene N.V.
- 13.8.1 Company Overview
- 13.8.2 Neurogenetic Diagnostic Portfolio
  - 13.8.2.1 Rare Neurological Disease Panels
  - 13.8.2.2 Whole Genome Sequencing Services
- 13.8.3 Key Applications
- 13.8.4 Strategic Collaborations
- 13.8.5 Financial Overview
13.9 Blueprint Genetics Oy
- 13.9.1 Company Overview
- 13.9.2 Neurological Disorder Testing Portfolio
  - 13.9.2.1 Epilepsy Panels
  - 13.9.2.2 Neurodevelopmental Disorder Panels
- 13.9.3 Key Applications
- 13.9.4 Strategic Developments
- 13.9.5 Financial Overview
13.10 Eurofins Scientific
- 13.10.1 Company Overview
- 13.10.2 Neurogenetic Testing Services
  - 13.10.2.1 Neuromuscular Disorder Panels
  - 13.10.2.2 Hereditary Ataxia Testing
- 13.10.3 Key Applications
- 13.10.4 Strategic Initiatives
- 13.10.5 Financial Overview

14. Future Outlook

14.1 Future Market Projections
14.2 Emerging Technology Trends
14.3 AI-Driven Genomic Interpretation Outlook
14.4 Expansion of Precision Neurology
14.5 Future Regulatory Evolution
14.6 Future Reimbursement Trends
14.7 Strategic Recommendations for Stakeholders
14.8 Opportunities in Emerging Markets
14.9 Long-Term Innovation Outlook

15. Methodology

15.1 Research Methodology Overview
15.2 Secondary Research Sources
15.3 Primary Research Methodology
15.4 Market Size Estimation Models
15.5 Forecasting Methodology
15.6 Data Triangulation Approach
15.7 Assumptions and Limitations
15.8 Abbreviations and Definitions